Table 2.

Clinical scores of 29 pediatric localized scleroderma patients over two study visits, by group^*. Changes in scores were compared between groups to determine contrasted group validity. Bolded results indicate significant median differences between groups

Score	Group* (by physician classification) Change (n = 15) No change (n = 14)	Median at v1	Median at v2	Change in score† (v1 – v2) Median (IQR)	Standardized Test statistic	p
Disease Activity Scores (physician)
mLoSSI	Change	6	0	6.0 (4 – 8)	3.15	< .01
	No change	0	0	0.0 (0.0 – 1.5)
PGA-A	Change	45	0	41.0 (34 – 51)	3.24	<.01
	No change	0	0	0.0 (0.0 – 12.5)
Disease Damage Scores (physician)
LoSDI	Change	7	5	2.0 (1 – 3)	0.58	.56
	No change	8	6.5	1.5 (0.0 – 3)
PGA-D	Change	35	18	14.0 (7 – 23)	1.27	.21
	No change	36	26	6.5 (3.8–13.5)
Global Disease Severity Scores (parent/patient)
Parent Global	Change	33	22	0.0 (−8 – 24)	−1.64	.10
	No change	71	41	22.0 (7.5 – 36)
Patient Global	Change	11	22	0.0 (−12 – 9)	−0.55	.58
	No change	41	28	10.0 (−14 – 23.5)
Quality of Life Score (patient)
CDLQI	Change	3	2	1.0 (−1 – 1)	−1.00	.32
	No change	6.5	6.0	1.0 (−1.5 – 6.5)

^*Physician assessment of disease activity was used to classify patients into two groups; those experiencing a change in disease activity over two time points (change) and those who did not experience a change in disease activity (no change).

^†The changes in all clinical scores were calculated by subtracting the score at v1 by the score at v2 (v1 – v2). v1 = initial study visit, v2 = secondary study visit, mLoSSI = modified Localized Scleroderma Severity Index, PGA-A = Physician Global Assessment of Activity, LoSDI = Localized Scleroderma Damage Index, PGA-D = Physician Global Assessment of Damage, Parent Global = Parent Global Assessment of Disease Severity, Patient Global = Patient Global Assessment of Disease Severity, CDLQI = Children’s Dermatology Life Quality Index.